Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
9 people get UCBJY.PK articles and Market Currents by email alert.
Get email alerts on UCBJY.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012
To learn more about Seeking Alpha Pro, click here.
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012
There are no Transcripts on UCBJY.PK.
There are no News articles on UCBJY.PK.
UCBJY.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for UCBJY.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 28, 2011, 3:02 AM Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37. Comment! [Healthcare]
There are no StockTalks on this stock yet.